NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Peptide testing

Ordered peptides from ZLZ Peptide? Mail in a sample (US only) and let us test it.

Test my supply
+6 more ↓
70%
Finnrick rating
#305 of 489 ranked vendors
248 of 311 classifiable tests passed
methodology · Purity focus
Finnrick analysis

ZLZ Peptide's purity-focus record is broad and recent, led by Retatrutide, Tirzepatide, and GHK-Cu but still marked by purity, fill, or identity outliers. Results are dispersed: Tesamorelin, BPC-157, TB-500, and NAD+ show repeated purity or quantity misses, while spotty batch IDs limit traceability despite some later improvement.

methodology →
vendor intelligence report
Vendor Intelligence Report: ZLZ Peptide

Corporate and B2B records trace ZLZ’s storefront to a Hunan chemical-intermediate operator with BMK/PMK precursor listings. The report also maps altered-COA allegations, alias-led sales channels, irreversible payment rails, and lookalike-domain risk.

30 pages7 risk factors assessed3 Jul 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
Retatrutide
$0.81
89%
117
2
Tirzepatide
$0.43
85%
97
3
GHK-Cu
$0.07
85%
19
5
PT-141
$0.62
72%
3
6
Semaglutide
$0.49
69%
13
7
Melanotan II
$0.54
66%
2
9
Sermorelin
$1.52
55%
5
10
BPC-157
$0.68
49%
13
11
Tesamorelin
$2.00
44%
18
12
CJC-1295
-
43%
5
13
TB-500
$1.76
38%
6
14
NAD+
$0.02
18%
5
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%13 Jul 2026: 70%13 Jul 2026: 70%15 Jul 2026: 70%15 Jul 2026: 70%15 Jul 2026: 70%15 Jul 2026: 70%23 Jul 2026: 70%23 Jul 2026: 70%23 Jul 2026: 70%5 Aug 2026: 70%5 Aug 2026: 70%5 Aug 2026: 70%6 Aug 2026: 70%6 Aug 2026: 70%9 Aug 2026: 71%12 Aug 2026: 71%13 Aug 2026: 71%21 Aug 2026: 71%25 Aug 2026: 71%4 Sep 2026: 71%4 Sep 2026: 71%5 Sep 2026: 71%8 Sep 2026: 71%15 Sep 2026: 71%21 Sep 2026: 71%23 Sep 2026: 71%24 Sep 2026: 71%24 Sep 2026: 71%24 Sep 2026: 71%30 Sep 2026: 71%30 Sep 2026: 71%1 Oct 2026: 71%5 Oct 2026: 70%5 Oct 2026: 70%5 Oct 2026: 70%6 Oct 2026: 70%6 Oct 2026: 70%8 Oct 2026: 70%12 Oct 2026: 70%12 Oct 2026: 70%10 Nov 2026: current 70%70%71%70%Jul 26Nov 26
Peptide testing

Ordered peptides from ZLZ Peptide? Mail in a sample (US only) and let us test it.

Test my supply
ZLZ Peptide test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
12 Oct 2026
Fail
Retatrutide
lab nameView COA
12 Oct 2026
Pass
Tirzepatide
lab nameView COA
8 Oct 2026
Pass
Retatrutide
lab nameView COA
6 Oct 2026
Fail
NAD+
lab nameView COA
6 Oct 2026
Pass
Retatrutide
lab nameView COA
5 Oct 2026
Pass
Retatrutide
lab nameView COA
5 Oct 2026
Fail
Retatrutide
lab nameView COA
5 Oct 2026
Fail
Retatrutide
lab nameView COA
1 Oct 2026
Fail
Semaglutide
lab nameView COA
30 Sep 2026
Pass
Retatrutide
lab nameView COA
1-10 of 200

About ZLZ Peptide test results from Finnrick

ZLZ Peptide is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 14 peptides and 312 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible ZLZ Peptide peptides in this dataset are Retatrutide (117 tests) and CJC-1295 (5 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 200 recent tests.

Corrections
No corrections.
Peptide testing

Ordered peptides from ZLZ Peptide? Mail in a sample (US only) and let us test it.

Test my supply